Hongwei Zhang

Dr. Hongwei Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
WNWeihai Ning
Weihai Ning
ZQZhiqiang Qiu
Zhiqiang Qiu
XJXiangwen Ji
Xiangwen Ji
XWXiang Wang
Xiang Wang
YAYihua An
Yihua An
HZHongwei Zhang
Hongwei Zhang

16 November 2023 in Life Sciences
Verified
Journal Article
Closed access
SLShenglun Li
Shenglun Li
YGYuduo Guo
Yuduo Guo
WNWeihai Ning
Weihai Ning
YCYujia Chen
Yujia Chen
JXJiacheng Xu
Jiacheng Xu
HZHongwei Zhang
Hongwei Zhang

18 December 2020 in Medicine
Verified
Journal Article
Open access
XWXiang Wang
Xiang Wang
WNWeihai Ning
Weihai Ning
ZQZhiqiang Qiu
Zhiqiang Qiu
SLShenglun Li
Shenglun Li
HZHongwei Zhang
Hongwei Zhang
CYChunjiang Yu
Chunjiang Yu
Tumor-associated macrophages (TAMs) play a crucial role in the immune response to many malignancies, but the signaling pathways by which the glioma microenvironment cross-talk with TAMs are poorly understood. The aim of this study was to uncover the potential signaling pathways of the regulation of TAMs and identify candidate targets for therapeutic intervention of glioma through bioinformatics analysis. Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets were used to download RNA-Seq data and microarray data of human glioma specimen. Differentially expressed genes (DEGs) between CD68-high samples and CD68-low samples were sorted. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the DEGs was conducted. Protein-protein interaction (PPI) network were formed to identify the hub genes. The prognostic value of TAMs in glioma patients was confirmed. A total of 477 specific DEGs were sorted. The signaling pathway was identified in pathway enrichment and the DEGs showed prominent representations of immune response networks in glioma. The hub genes including C3, IL6, ITGB2, PTAFR, TIMP1 and VAMP8 were identified form the PPI network and they were all correlated positively with the expression of CD68 and showed the excellent prognostic value in glioma patients. TAMs can be used as a good prognostic indicator in glioma patients. By analyzing comprehensive bioinformatics data, we uncovered the underlying signaling pathway of the DEGs between glioma patients with high and low expression level of CD68. Furthermore, the 6 hub genes identified were closely associated with TAMs in glioma microenvironment and need further investigation.

1 November 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
XWXiang Wang
Xiang Wang
ZQZhiqiang Qiu
Zhiqiang Qiu
XJXiangwen Ji
Xiangwen Ji
WNWeihai Ning
Weihai Ning
YAYihua An
Yihua An
HZHongwei Zhang
Hongwei Zhang
Background: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multiple clinical values, liquid biopsies are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Additionally, blood biomarkers which were found using data-driven methods may only be effective in few datasets. Methods: We firstly collected the genes which have expression correlations between blood and the other tissues/organs using Genotype-Tissue Expression (GTEx). Survival hazard genes and differential expression genes of each cancer type in The Cancer Genome Atlas (TCGA) were then selected by Cox regression model and Wilcoxon rank sum test, respectively. By combining the P values of two steps, several blood biomarkers can be inferred for each cancer type. After applying these potential blood biomarker sets to 13 datasets of blood samples from solid tumor patients using single sample gene set enrichment analyses (ssGSEA), we got an enrichment score (ES) for each sample. Results: The inferred blood biomarker (BB infer) genes showed reliable predictive value in various malignancies. In all the blood samples that were analyzed, the ESs of positive BB Infer genes in cancer patients are higher than healthy people. Conversely, the ESs of negative BB Infer genes in cancer patients are lower than healthy people. Furthermore, lower ES of negative BB infer genes signify the dismal outcome of patients. Conclusions: We developed a novel solid tumor blood biomarker inference workflow for cancer screening and diagnosis. Moreover, we demonstrated the utility of this inference method in a series of blood sample datasets of solid tumor patients. These results suggested the potential value of this method in the screening, diagnosis and prognosis of cancers.